Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study

Verfasser / Beitragende:
[Irene-Ariadne Kechagia, Aristides Dokoumetzidis]
Ort, Verlag, Jahr:
2015
Enthalten in:
Journal of Pharmacokinetics and Pharmacodynamics, 42/3(2015-06-01), 237-250
Format:
Artikel (online)
ID: 605533857
LEADER caa a22 4500
001 605533857
003 CHVBK
005 20210128100840.0
007 cr unu---uuuuu
008 210128e20150601xx s 000 0 eng
024 7 0 |a 10.1007/s10928-015-9412-6  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10928-015-9412-6 
245 0 0 |a Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study  |h [Elektronische Daten]  |c [Irene-Ariadne Kechagia, Aristides Dokoumetzidis] 
520 3 |a A preliminary population pharmacokinetic (PopPK) model of valacyclovir in children was developed from non-compartmental analysis (NCA) parameter values from literature, including several age groups, combined with Bayesian priors from a PopPK model of acyclovir, the active metabolite of valacyclovir, from literature too. Also a simulation study was carried out to evaluate the performance of various modelling choices related to the estimation of model parameters from NCA parameters originating from sparse PK studies. Assuming a one-compartment model with first order absorption, a mixed effects, meta-analysis approach was utilized which allows accounting the random intergroup variability, the detection of covariates and the application of informative Bayesian priors on the parameters. The conclusions from the simulation study calculating bias and precision for various cases, were that a model which takes explicitly into account the sampling schedule, performs better than a model using the theoretical expressions of calculating the NCA parameters. Also by using the geometric rather than the arithmetic means of NCA parameters, less biased results are obtained. These findings guided the choices for the valacyclovir model, for which informative priors from a PopPK model of acyclovir were applied for some of the parameters, in order to include a richer covariate model for clearance, not supported by the NCA dataset and a value for bioavailability. This preliminary valacyclovir model can be used in simulations to provide dosage recommendations for children of various ages and to help design more efficiently prospective clinical trials. 
540 |a Springer Science+Business Media New York, 2015 
690 7 |a Bayesian priors  |2 nationallicence 
690 7 |a Meta-analysis  |2 nationallicence 
690 7 |a Paediatric pharmacokinetic model  |2 nationallicence 
700 1 |a Kechagia  |D Irene-Ariadne  |u School of Pharmacy, University of Athens, Panepistimiopolis, 15771, Athens, Greece  |4 aut 
700 1 |a Dokoumetzidis  |D Aristides  |u School of Pharmacy, University of Athens, Panepistimiopolis, 15771, Athens, Greece  |4 aut 
773 0 |t Journal of Pharmacokinetics and Pharmacodynamics  |d Springer US; http://www.springer-ny.com  |g 42/3(2015-06-01), 237-250  |x 1567-567X  |q 42:3<237  |1 2015  |2 42  |o 10928 
856 4 0 |u https://doi.org/10.1007/s10928-015-9412-6  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10928-015-9412-6  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kechagia  |D Irene-Ariadne  |u School of Pharmacy, University of Athens, Panepistimiopolis, 15771, Athens, Greece  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Dokoumetzidis  |D Aristides  |u School of Pharmacy, University of Athens, Panepistimiopolis, 15771, Athens, Greece  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Journal of Pharmacokinetics and Pharmacodynamics  |d Springer US; http://www.springer-ny.com  |g 42/3(2015-06-01), 237-250  |x 1567-567X  |q 42:3<237  |1 2015  |2 42  |o 10928